Mazor Robotics Ltd – (NASDAQ:MZOR) fell 2.2% during mid-day trading on Monday . The stock traded as low as $23.22 and last traded at $23.33, with a volume of 109,537 shares. The stock had previously closed at $23.86.

Several research firms recently issued reports on MZOR. Needham & Company LLC reiterated a “hold” rating on shares of Mazor Robotics Ltd – in a report on Tuesday, May 10th. Zacks Investment Research upgraded Mazor Robotics Ltd – from a “sell” rating to a “hold” rating in a report on Tuesday, June 14th. Sterne Agee CRT cut Mazor Robotics Ltd – from a “buy” rating to a “neutral” rating in a report on Tuesday, May 31st. Barclays PLC lifted their price objective on Mazor Robotics Ltd – from $16.00 to $23.00 and gave the stock an “overweight” rating in a report on Thursday, July 14th. Finally, Wells Fargo & Co. upgraded Mazor Robotics Ltd – from a “market perform” rating to an “outperform” rating in a report on Thursday, May 19th. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Mazor Robotics Ltd – presently has a consensus rating of “Buy” and an average price target of $25.00.

The firm has a 50-day moving average of $20.78 and a 200 day moving average of $14.37. The company’s market cap is $509.10 million.

Mazor Robotics Ltd – (NASDAQ:MZOR) last announced its earnings results on Tuesday, August 2nd. The company reported ($0.09) EPS for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.02. During the same period in the previous year, the company posted ($0.05) earnings per share. The business earned $8.30 million during the quarter, compared to analysts’ expectations of $8.51 million. Mazor Robotics Ltd -‘s quarterly revenue was up 6.4% on a year-over-year basis. On average, equities analysts predict that Mazor Robotics Ltd – will post ($0.63) earnings per share for the current year.

Mazor Robotics Ltd is an Israel-based medical device company that develops and markets surgical guidance systems and complementary products. It develops computerized and imaging-based systems in the field of spine surgery. Its products include: Renaissance Surgical Guidance System, which enables surgeons to advance from freehand surgical procedures to guided procedures, as well as Food and Drug Administration (FDA)-cleared and European Conformity (CE)-marked Renaissance System, used in spine surgeries, whether open or minimally invasive, for a number of clinical indications.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.